ignore the crowd, page-5

BKL have performed well over the course of the year both in terms of share price and operational.
The recent sell down saw bkl go to the $18 levels. A buy for a great growth security. Although they are on a high p/e multiple to the market, they have continued strong growth rates which have continued for the past 10 years. A great indicator that will continue to produce and sell. Earnings have performed well and there is little if any debt that this company holds. [A prime takeover or LBO target... you would think so, with the amount of cash in the market - but founder Mr Blackmore holds the majority stake, so if the price aint right, he aint selling.] There is also a very small shareholder base, a positive in my books although some may disagree.
I am a holder of bkl. They have a strong branding presence in all areas of the vitamin/health care market. This type of moat produced over the company's history can only increase.